Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting under SEBI LODR Regulations 30 & 33
Audit Opinion:
The statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified report for both the standalone and consolidated financial results.
Auditor’s Comment:
The limited review concluded that nothing came to their attention to believe the statements were not prepared in all material respects in accordance with Ind AS and SEBI LODR requirements.
Key Financial Highlights [₹ in Crores]
Standalone Results:
Revenue from Operations: ₹2,974 (Q1 FY27) vs ₹2,357 (Q1 FY26) — 26.2% YoY increase.
Total Income: ₹3,037 (Q1 FY27) vs ₹2,476 (Q1 FY26)
Net Profit: ₹891 (Q1 FY27) vs ₹557 (Q1 FY26) — 60.0% YoY increase.
EPS: Basic and Diluted EPS of ₹33.55 (Q1 FY27) vs ₹20.95 (Q1 FY26)
Other Equity: Not specified for current quarter; was ₹16,658 as of March 31, 2026.
Cash and Cash Equivalents: Not Specified
Debt: Not Specified
Consolidated Results:
Revenue from Operations: ₹3,080 (Q1 FY27) vs ₹2,410 (Q1 FY26) — 27.8% YoY increase.
Total Income: ₹3,144 (Q1 FY27) vs ₹2,529 (Q1 FY26)
Net Profit: ₹902 (Q1 FY27) attributable to shareholders vs ₹545 (Q1 FY26) — 65.5% YoY increase.
EPS: Basic and Diluted EPS of ₹33.95 (Q1 FY27) vs ₹20.49 (Q1 FY26)
Other Equity: Not specified for current quarter; was ₹16,708 as of March 31, 2026.
Cash and Cash Equivalents: Not Specified
Debt: Not Specified
Segment-wise Performance:
The Company and the Group operate in a single reportable business segment: 'manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients' as per Ind AS 108.
Corporate Actions:
Not Specified
Other Significant Information:
Appointment of Senior Management Personnel:
The Board approved the appointment of the following as Senior Management Personnel, effective August 01, 2026:
- Mr. B. Vara Prasad as General Manager (Engineering Purchase). He holds an MBA and has over 31 years of experience in pharmaceutical procurement, specializing in capital equipment and project commissioning.
- Mr. J. Srinivasa Rao as General Manager (Raw Materials Purchase). He holds an MBA and has over 30 years of experience, specializing in strategic sourcing and management of raw material procurement.
Forex Gain/(Loss):
Standalone: Loss of ₹7 crores for Q1 FY27 vs a Gain of ₹39 crores for Q1 FY26.
Consolidated: Loss of ₹7 crores for Q1 FY27 vs a Gain of ₹39 crores for Q1 FY26. Losses are included in 'Other expenses' and gains in 'Other income'.
Exceptional Items:
An exceptional item of ₹74 crores, described as 'Impact of New Labour codes', was recorded for the full year ended March 31, 2026. There were no exceptional items in Q1 FY27.